EGFR+ Lung Cancer

Osimertinib Achieves Extended Disease-Free Survival in EGFR-Mutant NSCLC

September 21, 2020

In patients with early-stage EGFR mutated non–small cell lung cancer following complete tumor resection, treatment with osimertinib reduced the risk for central nervous system death or progression by 82%, findings presented during the EMSO Virtual Congress 2020.

Adding Bevacizumab to Osimertinib Failed to Improve PFS in EGFR T790M+ Lung Cancer

September 21, 2020

Osimertinib plus bevacizumab did not lead to a prolonged progression-free survival compared with osimertinib alone as treatment of patients with advanced adenocarcinoma harboring EGFR T790M.

Responses, Favorable Safety Profile Reported for Amivantamab Plus Lazertinib in EGFR+ NSCLC

September 20, 2020

Findings from the phase 1 CHRYSALIS study showed that patients with advanced EGFR-mutant non–small cell lung cancer who were treatment naïve or resistant to osimertinib therapy had high response rates when treated with the combination of amivantamab and lazertinib. Results also demonstrated a favorable safety profile for the regimen, according to results reported at the ESMO Virtual Congress 2020.

EGFR+ NSCLC Treated in the Frontline With Osimertinib/Apatinib Combination Has PFS Improvement

September 20, 2020

The combination of apatinib and gefitinib demonstrated the feasibility of dual VEGFR/EGFR inhibition in patients with advanced EGFR-mutant non–small cell lung cancer, according to progression-free survival results of the phase 3 ACTIVE trial that were reported at the ESMO Virtual Congress 2020.

No PFS Improvement Is Seen With EGFR/VEGF Inhibitor Combo

September 20, 2020

Patients with advanced lung adenocarcinoma who harbor EGFR T790M mutations did not experience significant progression-free survival improvement with osimertinib plus bevacizumab versus osimertinib alone, according to findings presented by Yukihiro Toi, MD, during the 2020 European Society for Medical Oncology Virtual Congress.

Clinical Trials Excite Treatment Landscape for Early-Stage EGFR-Mutated NSCLC

September 18, 2020

Balazs Halmos, MD, MS, discusses 2 major presentations from the 2020 American Society of Clinical Oncology Virtual Scientific Program that appeared promising for the treatment of patients with EGFR-mutant non–small cell lung cancer.

Pennell Examines Targeted Therapies in EGFR-Mutated NSCLC

September 13, 2020

Nathan A. Pennell, MD, PhD, discussed the case of 66-year-old patient with EGFR-mutant non–small cell lung cancer, during a virtual Case Based Peer Perspectives event.

Osimertinib Shows No OS Benefit Versus Chemotherapy in EGFR T790M-Mutant Advanced NSCLC Study

September 03, 2020

A statistically significant overall survival benefit was not observed with osimertinib compared with platinum-pemetrexed therapy as treatment of patients with EGFR T790M-mutated advanced non–small cell lung cancer.

Real-World Study Expands Benefit-Risk Assessment Data for Osimertinib in EGFR+ NSCLC

September 03, 2020

The benefits and risks of osimertinib as second- or later-line treatment of patients with EGFR-positive non–small cell lung cancer that were reported when the agent was first approved, have now been confirmed, according to data from a real-world study conducted in Japan.

GioTag Update: Final OS Promising for Sequential Afatinib Following Osimertinib in EGFR+ NSCLC

September 02, 2020

Sequential afatinib followed by osimertinib led to encouraging outcomes in patients with deletion 19 (del19) or L858R epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer, according to the final analysis results from the real-world study, GioTag.